How Molecular Biomarkers Have Impacted Cancer Treatment

Geoff Oxnard, MD
Thoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Lauren Ritterhouse, MD, PhD
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.
Related Articles
Navigating Lung Cancer Patients at Fox Chase Cancer Center
August 2018 Vol 9, No 8
An Interview with Maria Kadlec, BSN, RN; Caryn M. Vadseth, BSN, RN, OCN; and Mary Pat Winterhalter, MS, BSN, RN, NE-BC
Best Practices in Incorporating Biomarker Testing to Deliver Precision Therapy in Cancer
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Best Practices in Immuno-Oncology Biomarker Testing - August 2018

The target audience for this series includes physicians (medical and surgical oncologists, interventional radiologists), oncology nurse navigators, oncology nurses, pathologists, oncology pharmacists, and other stakeholders involved in delivering personalized care to cancer patients.

Highlights

Optimizing Communication Between Oncologists and Pathologists on Cancer Biomarker Testing
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the best ways oncologists and pathologists can communicate about molecular biomarker testing for individual patients as well as on strategies for incorporating new biomarkers into testing panels.
Last modified: July 30, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code